Nano-x Imaging Ltd · NASDAQ:NNOX
Nano-x Imaging — Investor Day (December 2023)
62 slides from Nano-x Imaging's investor day presentation, Dec 4, 2023
Slide 1: Investor Day December 2023
Investor Day December 2023
Slide 2: Disclaimers
Edn Nanox Investor Day Disclaimer Disclaimers This presentation has been prepared by NANO-X IMAGING LTD ("Nanox" or the *Company") and includes market data and other “information from sources believed by the Company to be reliable. For ple, industry and market data, including Nanox’s own research, b
Slide 3: On the agenda
LE rar. Nanox Investor Day On the agenda Erez Meltzer Chief Executive Officer and Board Member Opening remarks Erez Meltzer Chief Executive Officer and Board Member Innovation U.S. go - to - market fir | "General Manager, ARC division Global Commercialization Regulatory pathway Jim Dara General Mana
Slide 4: Opening Remarks
Erez Meltzer Chief Executive Officer _ Opening Remarks .— SZ S> = 4 > 2 0 x
Slide 5: The Nanox Impact
g2 NaNnox Opening Remarks Nanox Investor Day | 5 The Nanox Impact Patient Centric A Innovation Technology Maximizing Advocacy Commercial Efficiency rel - Acceleration
Slide 6: The Nanox Culture
g? NaNox Opening Remarks Nanox Investor Day The N Culture Resilience Winning Spirit Passion Agility & Flexibility Dedication | - Creativity
Slide 7: Innovation in medical technology and AI for global health equity
Opening Remarks Nanox Investor Day Innovation in medical technology, and Al is crucial for achieving global health equity.
Slide 8: U.S. Go-to-Market
Erez Meltzer Chief Executive Officer U.S. Go-to-Market S= SW ZB SS" 4 > 2 0 x
Slide 9: FDA Clearance April 2023
USS, Go-to-Market a BAN CLEARED FDA Clearance Apri 2023
Slide 10: First U.S. Demo Center
U.S. Go-to-Market Nanox Investor Day FIRST U.S. DEMO CENTER US. Go-to-Market ‘Nanax investor Day | 10. FIRST U.S. DEM@CENTER ye — 2 oa °<
Slide 11: Demonstration center for the Nanox.ARC
GE rar. Nanox Investor Day Demonstration center for the Nanox.ARC, which will provide potential buyers with a live demonstration of the technology, and a clinical site that can raise awareness of the Nanox.ARC among key opinion leaders, radiologists, and hospital system personnel Commercial use
Slide 12: U.S. Go-to-Market strategy
g2 NaNnox U.S. Go-to-Market Nanox Investor Day | 12. U.S. Go-to-Market strategy Our U.S. go to market strategy is comprised of three primary components: = oa ustomer 22, Building a (ee Using a Hybrid / Targeting \ Sales Team \_/ Business Model eo A © TS
Slide 13: Customer Targeting: Type of medical facility
U.S. Go-to-Market Customer Targeting 0 Type of medical facility Imaging Center Orthopedic Clinic Urgent Care Skilled Nursing Facilities
Slide 14: Customer Targeting: Current imaging capabilities
U.S. Go-to-Market Customer Targeting 0) 2 Current imaging capabilities 7 -15 studies per day
Slide 15: Customer Targeting: Geographic location
U.S. Go-to-Market Customer Targeting Cluster 1: 0) Geographic location, New England namely rural vs. urban Leveraging CT & SNF / FSED / UC density and Medicare enrollment, the Atlantic region may i : ji Cluster 2: offer strong ceporttniey for TS; ust targeting Merle atlantic may support efficient Na
Slide 16: Nanox.ARC U.S. organization and network
GE rare U.S. go-to-market Nanox Investor Day Nanox. ARC U.S. Professional Network ii Marketing Legal & Regulatory Affairs Finance _ &Billing Sale Representatives Clinical & Medical Affairs / “— _-USARAD Network Maintenance’ & Customer x Support io Partners Corporate Resources
Slide 17: Holistic Customer Support
BE vance U.S. Go-to-Market Nanox Investor Day Holistic Customer Support Nanox.ARC Call Center (Global) 626 Activity Alignment Escalation Specialist Reporting & Follow-up Nanox.ARC Status Tracking; logging, scans, errors, maintenance indications Potential Future Sales & Distribution Partner On-site T
Slide 18: Image Academy
U.S. Go-to-Market 626 Image Academy
Slide 19: U.S. Business Model
ZF nanox U.S. Go-to-Market Nanox Investor Day U.S. Business Model S ¢ CAPEX and MSAAS “es Hybrid, with financing Per scan Per System $30 Scans 7 -15 per day
Slide 20: Global Commercialization / Regulatory Pathway
Ofir Koren General Manager, ARC Division Global Commercialization Regulatory Pathway .— SZ S> = 4 > 2 0 x
Slide 21: Global Commercialization
Global Commercialization Nanox — Investors Day
Slide 22: Global Commercialization Insights
Global Commercialization Nanox Investor Day Insights 205° BC te iraaes
Slide 23: Global Commercialization
Global Commercialization
Slide 24: Clearance/approval status by country
US. Israel Ghana Current Clearance/approval FDA 510(k) | MSK AMAR GFDA | Msk | Whole Body Submitted | Whole Body Future submission FDA 510(k) | Chest
Slide 25: Clinical Trial
Clinical Trial RABIN MEDICAL CENTER BEILINSON #e HASHARON SHAMIR MEDICAL CENTER
Slide 26: Clinical Benefits and Nanox.AI
Dr. Orit Wimpfheimer Chief Medical Officer * Clinical Benefits + Nanox.Al S= SW ZB SS" 4 > 2 0 x
Slide 27: Tomosynthesis: Place in Medical Imaging
FF vanox Clinical Benefits Nanox Investor Day Tomosynthesis — Place in Medical Imaging Multiple Modality Thoracic Imaging and Product Comparison ds Tomosynthesis Partially overlapping anatomy Body structures separated Relatively low dose Relatively high dose X-ray Overlapping body structures (2D) Re
Slide 28: Tomosynthesis Clinical Benefits
g? Nanox Clinical Benefits Nanox Investor Day | 28 Tomosynthesis Clinical Benefits The MSK applications of tomosynthesis compares to X-ra * Improved visualization of occult bone fractures * Delineate complex anatomic structures * Decreased interference from cast ° Decreased effect of metal artifacts
Slide 29: Right Hand: Nanox.ARC Tomosynthesis
FF vanox Clinical Benefits Nanox Investor Day Right Hand Nanox.ARC Tomosynthesis A SHAMIR Image was taken under Helsinki permit to conduct a clinical study in Israel, using our multisource jealthy volunteer) Ag mere. y a CentER Nanox.ARC system, 2023. Image courtesy of Shamir Medical Center
Slide 30: Left wrist with cast
FF vanox Clinical Benefits Nanox Investor Day Left wrist with cast ee (Healthy volunteer) ARG) RESME tmave was taken under Helsinki permit to conduct a cnical study in ftae, using our musource CENTER Nanox.ARC system, 2023. Image courtesy of Shamir Medical Center
Slide 31: Pelvis with sclerotic lesion
FF vanox Clinical Benefits Nanox Investor Day Pelvis with sclerotic lesion Healthy volunteer] SHAMIR mage was taken under Helsinki permit to conduct a clinical study in Israel, using our multisource EY YBBR Nanox anc system, 2023, Image courtesy of Shami Medical Center
Slide 32: Ankle fracture with cast
Clinical Benefits Ankle fracture with cast a Radiography
Slide 33: Radiograph vs Nanox.ARC Tomosynthesis
Clinical Benefits Radiograph Nanox.ARC Tomosynthesis \_ is
Slide 34: Thoracic spine and rib cage
FF vanox Clinical Benefits Nanox Investor Day Thoracic spine and rib cage FReciograph Momosynthesis Healthy volunteer] N stamie Image was taken under Helsinki permit to conduct a clinical study in Israel, using our multisource EY YBBR Nanox anc system, 2023, Image courtesy of Shami Medical Center
Slide 35: Tomosynthesis Clinical Benefits
SF vanox Clinical Benefits Nanox Investor Day Tomosynthesis Clinical Benefits Enhanced visualization to inform clinical decisions Reduced super-imposition of normal structures may reduce false positives and help with problem solving * Improved visualization of subtle findings * Improved detail and s
Slide 36: Covered Procedure and Flexible Business Model
FF vanox Clinical Benefits Nanox Investor Day Covered Procedure CPT° Code 76100 i Payment range $88-$109 (CMS) Higher reimbursement on top of radiography Flexible Business Model We intend to use a hybrid approach combining a usage based MSaaS model with and a CapEx model to help promote adoption, ba
Slide 37: Value Proposition for Nanox.ARC
SF vanox Clinical Benefits Nanox Investor Day Value Proposition for Nanox.ARC Nanox.ARC is an FDA-cleared digital multi-source 3D tomosynthesis imaging system, providing advanced radiographic visualization to enhance your pr. Nanox.ARC unlocks significant value for medical practices, providers Affor
Slide 38: Value Proposition for Nanox.ARC
SF vanox Clinical Benefits Nanox Investor Day Value Proposition for Nanox.ARC Nanox.ARC is an FDA-cleared digital multi-source 3D tomosynthesis imaging system, providing advanced radiographic visualization to enhance your pr. Nanox.ARC unlocks significant value for medical practices, providers Lever
Slide 39: Nanox.AI
wry a) Nanox.Al NANOX
Slide 40: Nanox.AI: Rabin Medical Center experience
Nanox.Al Nanox Investor Day 40 We have implemented NanoxAl HealthCCS solution in our HMO owned (Clalit) teaching hospital and have seen great value in identifying new patients with high calcium on chest CT scans. Even ina preventive oriented population as the one we have in our organization we were
Slide 41: Nanox.AI: Newly identified patients
Nanox.Al Nanox Investor Day Patients met inclusion Patients were included Of the 326 patients that were validated by radiology ith,available cardiac history, 27% newly identified patients with moderate coronary artery calcium were directed to PCP 31 % newly identified patients with severe coronary a
Slide 42: Nanox.AI
Nanox.Al
Slide 43: Nanox.AI and Spectrum Health
FF vanox Nanox.Al Nanox Investor Day Nanox.Al and Spectrum Health Putting preventive healthcare into practice January — September 2023; 2,441 new.CV 16,170 non-contrast chest CT Medium + High CAC: 6,641 (41%) a Results added to report: 3,894 (58.6%) Unknown CVD: (62.7%) 2,441 *8 months, including ra
Slide 44: Innovation
Erez Meltzer Chief Executive Officer Innovation S=. BZ S = 4 > 2 0 x
Slide 45: Nanox.CONNECT
TB nox Nanox.CONNECT
Slide 46: Clinical Care Workflow and Connectivity
SF vanox Innovation Nanox Investor Day Clinical Care Workflow and Connectivity Patient Results ‘ Results available for imaging facility, referring physician and patient Al service Modality (DX, ARC) 7 ‘ = ue PACS & EMR Radiology rand Al reports sent to PACS and EMR Findings are reviewed by radiologi
Slide 47: Real-Life Circumstances in Morocco
Real-Life Circumtances in Morocco
Slide 48: Nanox.CONNECT
Innovation NANOX CONNECT
Slide 49: Nanox.CONNECT dashboard
io) NANOx Innovation Nanox Investor Day | 49 e © O &@ app.powerbi.com: > DB Filey @ Share - '¢ Export » Teams Q Get insights G@ Subscribe to report Connect coon doy Lat 7dop Late ee Studies Summary Distibutor Total Acquired | Uploaded Studies by Body Part Ores a? koton ener cers sic enae n> v Mice H
Slide 50: Source & Services - OEM
Jim Dara GM Source & Services & Head of Nanox USA + Source & Services - OEM
Slide 51: Source and Services
JS vanox Nanox Investor Day | 511 Source and Services Source: Nanox Emitter 000000000 i aan ana0n nn nO 00 Identify and launch additional sources for Nanox OOOO OODOOO chips and enabled tubes OB0ABRAOa45 oon 00 00000 Generate awareness and demand for Nanox SODOOOOODD technologies across multiple ind
Slide 52: Nanox.Source Benefits
JS ranox Source and Services Nanox Investor Day | 52 Nanox.Source Benefits Partner feedback: High current density > 1 A per cm? Stable emission Flexible emitter activation Focal Spot flexibility Low gate voltage compared to CNT Ultra-fast X-ray switching: < Ips Smaller footprint
Slide 53: New Business Development Tool
3 Source and Services NANOx New Business Development Tool Not all entities have the internal expertise and equipment to assess Nanox technologies at the chip level > Nanox DEMO Includes the necessary hardware, software and certifications to activate our chip & tube > Allows for seamless pc connectio
Slide 54: Varex Strategic Relationship
Source and Services Nanox Investor Day 54 Varex Strategic Relationship Tube Development & Production Nanox.ARC System Integration New Application Development —- WwW VAREX IMAGING HQ October Kickoff | lopment & Prototyping Regulatory Production Nanox.ARC Delivery Testing Protocol Production Testing P
Slide 55: Additional Partnerships
io) NANOx Original Equipment Manufacturer Nanox — Investors Day Additional Partnerships After completing their own assessments of Nanox.SOURCE emitters: OF Industrial Having completed tube prototype development utilizing our emitter, we expect execution of a formal tube supply agreement with an indu
Slide 56: Financial Highlights
Ran Daniel Chief Financial Officer Financial Highlights
Slide 57: Q3/23 Financial Highlights
z >) NANOXx Financial Highlights Nanox Investor Day 57 Q3/23 Financial Highlights a —— $95.6M 4 a Worldwide Full Time Cash and CE as of Employees 9/30/23 $2.5M 67.3M (Q3/23) Fully Diluted Shares Revenue Outstanding
Slide 58: Closing Remarks
Erez Meltzer Chief Executive Officer Closing Remarks
Slide 59: 2024 Focus
io) NANOx Closing Remarks Nanox Investor Day | 59 2024 Focus cal) Commercial acceleration Cs) Business integration U.S ramp - up ( (© Regulation progress
Slide 60: Leading the Nanox Impact
Leading the Nanox IMPACT From Predictive to Preventive
Slide 61: Q&A Session
Q&A Session
Slide 62: Thank You!
Thank You!